A Phase 3 interventional study of BLB101 for Injection and Blinatumomab for Injection in Precursor B-cell Acute Lymphoblastic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Injectable BLB101 and Blincyto® in Adult Participants with R/R CD19+ B-ALL. Provide evidence for the approval and marketing of the drug for its targeted indication.
Primary Objectives:
Primary Endpoints:
This study plans to enroll approximately 212 participants, who will be randomized at a 1:1 ratio into the following two groups:
Test group: BLB101 for injection Control group: Blinatumomab for injection (Blincyto®) A stratified block randomization method will be adopted. The randomization stratification factors are as follows:a) Creatinine clearance (≤90 mL/min vs >90 mL/min);b) Baseline leukemic cell proportion (≤50% vs >50%);c) Relapsed/refractory status (first relapse vs ≥2 relapses or refractory disease).
For each participant, the overall study procedure is outlined as follows: Participants will receive treatment with either BLB101 for injection or Blincyto®. Each treatment cycle consists of 6 weeks, including 4 weeks of dosing followed by a 2-week treatment-free interval. Each participant is required to complete the first 2 induction treatment cycles (i.e., an induction treatment period of up to 12 weeks), after which the participant will be considered to have fulfilled the primary study objectives.
A Randomized, Double-Blind, Positive-Controlled, Multicenter Clinical Study to Compare the Similarities in Pharmacokinetics, Efficacy, Safety and Immunogenicity Between Injectable BLB101 and Blincyto® in Adult Participants with R/R CD19+ B-ALL. Provide evidence for the approval and marketing of the drug for its targeted indication.
Primary Objectives:
Primary Endpoints:
38 studies on the registry are indexed under Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; 16 are open to participants now.
This study's planned enrollment of 212 is above the median of 44 across 33 interventional studies indexed under Precursor B-Cell Lymphoblastic Leukemia-Lymphoma.
Browse Precursor B-Cell Lymphoblastic Leukemia-Lymphoma studies →Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following inclusion criteria to be included in this study:
Exclusion Criteria:
Participants who meet any of the following criteria are not eligible to be included in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BLB101 for injection administered via intravenous infusion at a dose of 9μg/d or 28 μg/d. One treatment cycle consists of 6 weeks, including 4 weeks of dosing followed by a 2-week treatment-free interval.Participants weighing ≥45kg received fixed dosing: In Induction Cycle 1: 9μg/d on Days1-7, followed by 28μg/d on Days 8-28, then a 14-day treatment-free period.In Induction Cycle 2: 28μg/d on Days 1-28, followed by a 14-day treatment-free period.For participants weighing \<45kg, doses were calculated by body surface area (BSA): Induction Cycle 1: 5μg/m²/d (max 9μg/d) on Days1-7, 15μg/m²/d (max 28μg/d) on Days8-28, followed by a 14-day treatment-free period; Induction Cycle 2: 15μg/m²/d (max 28μg/d) on Days1-28, followed by a 14-day treatment-free period.
Drug: BLB101 for Injection
Blinatumomab for injection administered via intravenous infusion at a dose of 9μg/d or 28 μg/d. One treatment cycle consists of 6 weeks, including 4 weeks of dosing followed by a 2-week treatment-free interval.Participants weighing ≥45kg received fixed dosing: In Induction Cycle 1: 9μg/d on Days1-7, followed by 28μg/d on Days 8-28, then a 14-day treatment-free period.In Induction Cycle 2: 28μg/d on Days 1-28, followed by a 14-day treatment-free period.For participants weighing \<45kg, doses were calculated by body surface area (BSA): Induction Cycle 1: 5μg/m²/d (max 9μg/d) on Days1-7, 15μg/m²/d (max 28μg/d) on Days8-28, followed by a 14-day treatment-free period; Induction Cycle 2: 15μg/m²/d (max 28μg/d) on Days1-28, followed by a 14-day treatment-free period.
Drug: Blinatumomab for Injection
BLB101 for Injection;Administration route: Intravenous infusion; Dose: 9 μg/day or 28 μg/day;Drug administration schedule: Each 6-week period constitutes a treatment cycle. During each cycle, the drug is administered for 4 weeks and then the drug is withheld for 2 weeks. Each participant is required to complete the first 2 treatment cycles. After completing the first 2 induction treatment cycles (i.e., a maximum of 12 weeks of treatment), they will be considered to have fulfilled the main research objective of this study. After 2 cycles of induction treatment, the decision will be made by the investigators based on the specific clinical circumstances.
Blinatumomab for Injection (Blincyto),Administration route: Intravenous infusion; Dose: 9 μg/day or 28 μg/day;Drug administration schedule: Each 6-week period constitutes a treatment cycle. During each cycle, the drug is administered for 4 weeks and then the drug is withheld for 2 weeks. Each participant is required to complete the first 2 treatment cycles. After completing the first 2 induction treatment cycles (i.e., a maximum of 12 weeks of treatment), they will be considered to have fulfilled the main research objective of this study. After 2 cycles of induction treatment, the decision will be made by the investigators based on the specific clinical circumstances.
Also known as: Blincyto
Css
Css(Steady-State Plasma Concentration)
Time frame: Cycle 1(Cycle 1=28 days), Day 8, Day 14, Day 21, Day 28, Day 29
AUC0-24,d1
Area under the plasma concentration-time curve from 0 to 24 hours on Day 1 (AUC0-24,d1)
Time frame: Cycle 1(Cycle 1=28 days), predose and up to 24 hourspost-dose
CR/CRh
Proportion of patients with Complete remission (CR) or complete remission with partial hematologic recovery(CRh)
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days)
Incidence of Adverse Events
Frequency, severity, and type of adverse events graded according to National CancerInstitute Common Terminology Criteria for Adverse Events (NCI CTCAE)Version (v) 6.0
Time frame: Up to 35 days after last dose / prior to subsequent anti-tumor therapy / prior to HSCT, whichever occurs first
Immunogenicity
ADA(anti-drug antibody) and Nab(neutralizing antibody)
Time frame: Cycle 1, predose and Day 29(Cycle 1=28 days); Cycle 2, Day 29(Cycle 2=28 days); or at the time of early participant withdrawal
T1/2
Plasma half-life
Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)
CL
CL(Clearance)
Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)
Vz
Vz(Terminal Apparent Volume of Distribution)
Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)
fluctuation coefficient
fluctuation coefficient
Time frame: Cycle 1, predose and Day 1, Day 8, Day 14, Day 21, Day 28, Day 29(Cycle 1=28 days)
CRR
CRR is defined as proportion of participants who achieve CR(Complete remission)
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
CRh
Proportion of participants who achieve CRh(Complete Remission with Partial Hematological Recovery)
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
CRi
Proportion of participants who achieve CRi(Complete Remission with Incomplete Hematological Recovery)
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
MLFS
Proportion of participants who achieve MLFS (Morphologic Leukemia-Free State)
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
ORR
Overall response rate(ORR) is defined as the percentage of patients achieving complete remission (CR) or complete remission with
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
DOR
Duration of remission(DOR) is time from first confirmed CR, CRi, CRh, MLFS or PR to first disease relapse or death from any cause, calculated separately by each best response category. For participants converting from initial CRi/CRh to subsequent CR, DOR start date remains the date of initial CRi/CRh.
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
Minimal Residual Disease(MRD) Negativity Rate
Proportion of patients achieving MRD negativity
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
EFS
Event-Free Survival (EFS) is defined as the time interval from the date of first study drug administration to the earliest occurrence of any of the following events: treatment failure, disease relapse, or death from any cause. Treatment failure is defined as failure to achieve CR, CRh, CRi, or MLFS after treatment. Notably, participants with EFS event attributed to treatment failure will be assigned an EFS duration of 1 day.
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
OS
Overall Survival (OS)) is defined as the duration of time from treatment initiation until the participant's death due to any reason.
Time frame: End of Cycle 1 and up to (+7) days (Cycle 1=28 days); End of Cycle 2 and up to (+7) days (Cycle 2=28 days); Completion of long-term follow-up period.
Proportion of lymphocyte subsets
Flow cytometry was used to determine the proportions of T cells (CD3+/CD4+/CD8+) and B cells (CD19+) to assess immune reconstitution status.
Time frame: Cycle 1, predose and Day 1, Day 8 (Cycle 1=28 days)
Serum concentration of IgG
Serum IgG was quantitatively tested to assess B cell functional recovery.
Time frame: Cycle 1, predose and Day 1, Day 8 (Cycle 1=28 days)
Plasma concentration of cytokines
Interleukin (IL)-2, IL-4, IL-6, IL-8, IL-10, IL-12, tumor necrosis factor alpha (TNF-α), interferon-γ (IFN-γ).
Time frame: Cycle 1, predose and Day 1, Day 8 (Cycle 1=28 days)
No study locations are listed for this record.
Plan to share: No — Individual participant data (IPD) will not be shared due to the sponsor's confidentiality policy and intellectual property restrictions.
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Oct 2027, 14 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma →
Institute of Hematology & Blood Diseases Hospital, China →